Monitoring movement in patients with ALS using a wearable device

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the daily movement patterns of patients with amyotrophic lateral sclerosis (ALS) using a novel device called Actimyo. Approximately 30 patients will be enrolled and monitored every three months for a year, during which they will wear the Actimyo device daily for one month after each visit. Participants will undergo clinical examinations and various tests, including the 6-minute walk test and electromyography, to evaluate their motor function and overall health. The study seeks to gather data on the impact of ALS on daily living activities through continuous monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.
* Over 18 years old.
* Signed informed consent
* If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.

Exclusion Criteria:

* Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
* Any other previous or present pathology having an impact on motor function.
* Recent surgery or trauma (less than 6 months) in the upper or lower limbs.
* Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.
* Patients participating in an interventional clinical trial.

Where it's running

• Katholieke Universiteit Leuven
  Leuven, Belgium Recruiting
• Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle
  Liège, Belgium Recruiting
• Galaa Military Medical Complex
  Cairo, Egypt Active not recruiting

Study contacts

• Principal investigator: Stéphanie Delstanche, MD — Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle
• Study coordinator: Laurie Medard
• Email: laurie.medard@citadelle.be
• Phone: +3243218222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Implanted Brain-Computer Interface to Help People with Severe Arm Impairment

  We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.

  Recruiting Neuralink Corp · Miami, Florida · NCT07929792

• Brain-computer interface chat tool for people with ALS

  This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.

  Recruiting Cognixion · Santa Barbara, California · NCT07871071

• BIIB147 safety and how it behaves in adults with ALS

  This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.

  Recruiting at 2 sites Phase 1/2 Biogen · St Louis, Missouri and 1 other locations · NCT07855211

• Aims to restore UNC13A function in people with ALS

  This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.

  Recruiting at 6 sites Phase 1/2 Trace Neuroscience, Inc. · Lübeck, Schleswig-Holstein and 5 other locations · NCT07674667

• LTX-002 in adults with ALS

  A study will test whether the experimental drug LTX-002 is safe and tolerable in adults with ALS and see how the body handles the drug and how it affects ALS indicators.

  Recruiting at 4 sites Phase 1/2 Leal Therapeutics, Inc · Lübeck and 4 other locations · NCT07660614

• Repeated ultrasound-assisted blood-brain barrier opening in ALS

  This trial tests whether repeatedly opening the blood-brain barrier with ultrasound is safe and may help people with ALS.

  Recruiting Phase 1/2 Assistance Publique - Hôpitaux de Paris · Paris · NCT07571486

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.